Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis
Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study
Elazığ Mental Health and Diseases Hospital
150 participants
Feb 3, 2025
OBSERVATIONAL
Conditions
Summary
This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.
Eligibility
Inclusion Criteria6
- Methamphetamine-Induced Psychotic Disorder (MP) Group:
- Diagnosis of MP according to DSM-5-TR
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- Methamphetamine-Induced Psychotic Disorder (MP) Group:
Exclusion Criteria10
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than MP
- Alcohol use disorder
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07459257